NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









CuraSen Therapeutics, Inc.

CuraSen Therapeutics, Inc.

Private
San Carlos, CaliforniaHealthcare & Life Scienceshttps://www.curasen.com/

Last Round

Series B

Aug 20, 2024

Est. Valuation

$123.5M

Total Funding Raised

$84.11M

Company Overview

CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small molecule drugs to treat a broad range of psychiatric and neurodegenerative diseases, including Parkinson's and Alzheimer's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryneurodegenerative diseasessmall moleculeGPCRG-protein coupled receptorsParkinson's diseaseclinical-stage biotechbiopharmaclinical trialstherapeutic developmentdrug pipelineCNS therapeuticspre-revenue biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CuraSen Therapeutics, Inc. Comparables

Compare CuraSen Therapeutics, Inc. with similar companies based on industry and business-model similarity.

CuraSen Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Athira Pharma
77%
Gain Therapeutics Inc
73%
AC Immune SA
73%

CuraSen Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 20, 2024
GrantOct 9, 2023
Series A ExtensionNov 5, 2021
Series AOct 17, 2018

Key People

Founding team and executive leadership

Michael D.

Chief Technology Officer

Executive Team

CuraSen Therapeutics, Inc. Investors

Notable investors and investment history

CuraSen Therapeutics, Inc. investors
InvestorRounds
Longitude CapitalSeries A
New Leaf Venture PartnersSeries A
A. M. Pappas & AssociatesSeries A Extension, Series A
Tekla Capital ManagementSeries A
Chiesi VenturesSeries A Extension
Johnson & Johnson Innovation - JJDC, Inc.Series A
ICG InfraSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2024

    $6M round led by ICG Infra.

  • Oct 17, 2018

    $55M round led by New Leaf Venture Partners.

CuraSen Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CuraSen Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CuraSen Therapeutics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Carlos, California
Employee Range20
Year Founded2018
Last FundingAug 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.